UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2026
(Commission File No. 001-43312)
Vicore Pharma Holding AB
(Translation of registrant’s name into English)
Kornhamnstorg 53
SE-111 27 Stockholm,
Sweden
(Address of registrant’s principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7): ☐
Company Announcement
On October 22, 2026, Vicore Pharma Holding AB (the “Company”) issued a press release announcing that the independent Data Monitoring Committee for the Phase 2b ASPIRE trial of buloxibutid in idiopathic pulmonary fibrosis has recommended that the trial continue without modification following a pre-planned futility analysis. The Company will continue the trial as planned. The press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
The information in the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Exhibits |
|
|
|
99.1 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Vicore Pharma Holding AB |
|
|
|
|
| By: | /s/ Ahmed Mousa |
| Name: Title: | Ahmed Mousa Chief Executive Officer |
Date: October 22, 2026